We assessed the extent and mechanisms of antagonism of beta-lactam antibiotics by cefoxitin. In tests with 41 gram-negative isolates, cefoxitin antagonized cephalothin, cefamandole, cefsulodin, cefotaxime, moxalactam, ampicillin, car-*benicillin, piperacillin, mezlocillin, and azlocillin, but not cephalexin, mecillinam, or N-formimidoyl thienamycin. The extent of antagonism varied with the betalactam and genus studied. However, antagonism occurred most often with strains possessing inducible cephalosporinases. Antagonism of cephalothin and cefamandole correlated closely with the induction of beta-lactamases capable of inactivating these drugs. Although antagonism of the remaining drugs occurred more often with strains possessing inducible beta-lactamases, these enzymes did not inactivate the drugs. Morphological studies revealed that cefoxitin inhibited filamentation and lysis produced by various beta-lactam drugs. Results of this investigation suggest that cefoxitin antagonizes beta-lactams via (i) induction of drug-inactivating beta-lactamases, and (ii) the induction of beta-lactamases that cannot inactivate the drug but serve as barriers against access to target proteins. This barrier appears most efficient for drugs that bind to penicillin-binding proteins 1 and 3.
. Solutions of each drug were prepared (weight corrected for potency) the day of use. Commercially prepared disks were either purchased from BBL microbiology associates, Cockeysville, Md. or kindly supplied by the drug manufacturer. These disks included ampicillin (10 ,ug) , carbenicillin (100 ,g), piperacillin (100 ,ug), azlocillin (75 ,ug), mezlocillin (75 ,ug) , mecillinam (16 Bacterial strains. The 41 strains tested were randomly selected clinical isolates representing those species of nonfastidious gram-negative bacilli commonly recovered from infected sites of hospitalized patients. They included 4 Escherichia coli, 3 Klebsiella pneumoniae, 3 Proteus mirabilis, 3 Citrobacter spp., 4 Serratia spp., 5 Enterobacter spp., 5 indole-positive Proteus spp., 4 Providencia spp., and 10 Pseudomonas aeruginosa. Enterobacter cloacae P99, a fully derepressed producer of type Ia cephalosporinase (6) , and its beta-lactamase-negative mutant, P99-(7), were kindly provided by L. Koupal of Merck, Sharp & Dohme.
Susceptibility tests. Minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) were determined by twofold dilution tests in 3 ml of Mueller-Hinton broth (MHB; Difco Laboratories) with an inoculum of 101 colony-forming units per ml. Tests were incubated for 18 h at 35°C in air. After incubation, 0.01-ml samples from each clear tube were subcultured to blood agar plates. The MBC was defined as the lowest concentration with no growth on subculture (99.9o kill).
Disk approximation tests for antagonism. The ability of cefoxitin to antagonize the activity of other beta- Resistant to cefoxitin in disk diffusion assays.
lactam antibiotics was determined in disk approximation tests, as described in detail previously (22) . Briefly, a cefoxitin disk producing no zone of inhibition was placed on a seeded plate at a distance from the test disk equivalent to the radius of the zone produced by the beta-lactam when tested alone. After overnight incubation at 35°C in air, the radii of the zone (i) between the cefoxitin and other beta-lactam disks and (ii) on the far side of the beta-lactam disk were measured. If the radius of (i) was smaller than that of (ii) by 4 mm or more, then antagonism was considexed to have occurred. For the marketed drugs, tests were performed only on those strains susceptible to the drugs in standard disk diffusion assays (16) . For the investigative drugs, tests were performed only on those strains giving zones of -15 mm in disk diffusion assays. Commercially prepared disks were used for all drugs except cephalexin and N-formimidoyl thienamycin. For these two drugs, disks were prepared the day of use from drug solutions. Disk approximation tests were performed with cefoxitin disks that gave no zone of inhibition for the test strain. For some strains, these were commercially prepared 30-,ug disks; for others, disks of lower potency were prepared from drug solutions ( Table 1) . Beta-lactamase assay. Enzyme inactivation of cephalosporins, moxalactam, and N-formimidoyl thienamycin was determined with whole cells, using a spectrophotometric assay described in detail previously (22) . Briefly, cells were suspended in phosphate buffer containing 100 ,uM of each drug. After incubation for 4 h at 37°C in air, the cells were removed by filtration. The amount of residual drug remaining after incubation was determined by measuring the absorbance at the wavelength corresponding to the beta-lactam ring. Inactivation of the penicillins was determined in a cylinder-cup bioassay, using Sarcina lutea (for penicillin G) or Bacillus subtilis ATCC 6633 (for other penicillins) as the assay organism. Beta-lactamases were induced by growing strains on MH agar (Difco) containing cefoxitin at the highest concentration that was not inhibitory to the test strain (22) . Enzymes were considered inducible if levels obtained in cells grown on the cefoxitin agar exceeded levels obtained in cells grown on drug-free agar by at least two standard deviations for the assay employed.
Morphological studies. Strains were inoculated into MHB, MHB with 30 F.g of cefoxitin per ml, MHB with other beta-lactams at a concentration equivalent to their MBC, and MHB with other beta-lactams plus cefoxitin. After incubation for 4 at 35°C in air, samples of each broth were removed and placed on cleaned glass slides. Cellular morphology was examined immediately by phase-contrast microscopy in simple wet mounts of each sample. Additionally, samples of each aliquot were heat-fixed and stained with methylene blue. These were examined under the high dry objective (50x), and photographs were taken with a microscope-mounted Zeiss 35-mm camera that provided an additional 12.5x magnification. Cellular morphology in wet mounts and stained preparations was the same.
RESULTS
Disk approximation tests for antagonism. Ce- foxitin's ability to antagonize the activity of other beta-lactam antibiotics correlated closely with the test strain's susceptibility to cefoxitin, as determined in disk diffusion tests (Tables 1  and 2 ). For most beta-lactams, antagonism was more likely to occur in tests with cefoxitinresistant strains than with susceptible strains.
For the "penicillin-group" beta-lactams ( 2), azlocillin was most frequently antagonized, followed by piperacillin, mezlocillin, and carbenicillin. Cefoxitin did not antagonize mecillinam or N-formimidoyl thienamycin. For the "cephalosporin-group" beta-lactams (Table 2) , cefotaxime was most frequently antagonized, followed by cefamandole and moxalactam. The activity of cefsulodin against Pseudomonas sp. was antagonized in several tests. No antagonism of cephalexin was observed.
Enzyme studies. Tests were performed on a number of the 41 isolates to determine the presence of cefoxitin-inducible beta-lactamases. For cephalothin and cefamandole, there was an association between the presence of inducible cephalosporinases active against these drugs and a positive disk test for antagonism ( Table 3) . The low prevalence of inducible enzymes capable of inactivating cephalexin in strains with negative tests for antagonism was similar to that observed for strains with negative antagonism tests for cefamandole and cephalothin. Two strains of Citrobacter spp. possessed cefoxitininducible cephalosporinases that inactivated cephalothin and cefamandole but not cephalexin. Cefoxitin antagonized the activity of the former two drugs but not cephalexin against these strains (Table 2) . Thus, the stability of cephalexin to these enzymes in part may have been responsible for the lack of antagonism of this drug by cefoxitin.
In of inducible cephalosporinase activity is summarized in Table 5 . Clearly, the presence of an inducible cephalosporinase was more predictive of antagonism than the susceptibility of the species to cefoxitin. To further assess the role of inducible betalactamases in the antagonisms observed, studies were performed with E. cloacae P99 and its beta-lactamase-negative mutant, P99-. The P99 strain was found to be resistant to all betalactam antibiotics evaluated in this except mecillinam and N-formimidoyl thienamycin. Disk antagonism tests with these latter two drugs were negative. Resistance precluded disk antagonism tests with the other drugs. The P99-strain was susceptible to all antibiotics, including cefoxitin. Disk antagonism tests with this strain were negative for all drugs. Enzyme assays revealed no beta-lactamase activity in P99-and noninducible penicillinase and cephalosporinase activity in P99. Among the substrates tested, the P99 strain inactivated penicillin G, cephalothin, cephalexin, cefamandole, and cefotaxime, but not moxalactam or N-formimidoyl thienamycin.
Morphological studies. Microscopic analyses were performed to determine the influence of cefoxitin on the morphological effects produced by beta-lactam antibiotics. For these studies, one strain each of E. cloacae and P. aeruginosa (both resistant to cefoxitin) was incubated in broth containing a variety of beta-lactams at their MBC, with and without 30 ,ug of cefoxitin per ml. After 4 h, cells were stained with methylene blue and examined for morphological effects produced by the beta-lactams. For the E. cloacae, cefoxitin inhibited cell lysis and disintegration ( Fig. 1E and F ) and decreased filamentation (Fig. 1C and D) induced by carbenicillin, mezlocillin, cefotaxime, moxalactam, and cefamandole. For the P. aeruginosa, cefoxitin (i) did not affect morphological changes induced by carbenicillin ( Fig. 2C and D) or mezlocillin, (ii) decreased lysis and filamentation produced by cefotaxime ( Fig. 2E and F) phological alterations were produced (Fig. 1B  and 2B) . DISCUSSION This study clearly indicated the ability of cefoxitin to antagonize a variety of beta-lactam antibiotics in vitro. These included many antiPseudomonas penicillins and "third-generation" cephalosporins. The frequency with which antagonism occurred was lowest in tests with strains lacking inducible cephalosporinases and highest with strains possessing such enzymes. Several possible mechanisms appeared to be responsible for the antagonisms observed; both involved beta-lactamases.
The first mechanism involved the induction of drug-inactivating enzymes by cefoxitin. This mechanism appeared to be responsible for the antagonism of both cephalothin and cefamandole. The low prevalence of inducible cephalosporinases in cephalothin-susceptible Enterobacteriaceae was probably responsible for the low frequency of antagonism of both cephalothin and cefamandole observed with these strains. Also, the stability of cephalexin to the inducible enzymes in these strains may explain the inability of cefoxitin to antagonize this drug.
The higher prevalence of inducible cephalosporinases in cephalothin-resistant Enterobacteriaceae, especially those also resistant to cefoxitin, was probably responsible for the more frequent antagonism of cefamandole by cefoxitin with these strains. Induction of drug-inactivating enzymes may also be in part responsible for the more frequent antagonism by cefoxitin of the ureidopenicillins in comparison to carbenicillin in tests with Pseudomonas sp., as the former are somewhat less stable to its beta-lactamase than is carbenicillin. However, increased inactivation of the ureidopenicillins by Pseudomonas sp. was not observed frequently, and antagonism of carbenicillin occurred in strains showing no inactivation of the drug. Thus, increased drug inactivation did not explain most instances of antagonism of either the anti-Pseudomonas penicillins or the third-generation cephalosporins by cefoxitin.
Cefoxitin antagonized the activity of the antiPseudomonas penicillins and third-generation cephalosporins most frequently in strains possessing inducible penicillinase-cephalosporinase activity. However, these enzymes did not appear to utilize the antagonized drug as a substrate in most instances. The inducible nature of these enzymes, their substrate profile, and their prevalence among strains of Enterobacter, indole-positive Proteus, Serratia, and P. aeruginosa suggest that they are very likely Richmond and Sykes type I enzymes (24) . Such betalactamases are characteristically inducible, chromosomally mediated cephalosporinases that also inactivate penicillin G, but at a much slower rate (10, 21, 24) . Cefoxitin, carbenicillin, cefotaxime, moxalactam, and cefsulodin are not good substrates for these enzymes (4, 12, 17, 19, 24) . However, the enzymes have a high affinity for these drugs and, consequently, their enzymatic activity is inhibited by the drugs (4, 19, 24) . Thus the antagonism of the anti-Pseudomonas penicillins and third-generation cephalosporins by cefoxitin may have occurred via a betalactamase-derived barrier mechanism. In this second mechanism, the increased levels of enzyme in the periplasmic space function as a barrier to nonsubstrate drugs and prevent their access to target proteins along the inner membrane. Such a barrier has been thought to be responsible for carbenicillin resistance in a mutant of P. aeruginosa derepressed for type I beta-lactamase production (24) , cefoxitin resistance in E. coli and E. cloacae producing high levels of cephalosporinase (17, 25) , and resistance to carbenicillin and sulbenicillin in E. coli and Salmonella typhimurium carrying plasmids for type IIIa and Va beta-lactamases (28) . Our results are the first indication that such a barrier mechanism may be responsible for antagonism between two drugs.
The data obtained with E. cloacae P99 and its mutant lend further support to this barrier mechanism. E. cloacae P99 produced the prototype Ia enzyme (24) , which is similar to those found in other strains of Enterobacter spp. except its production in P99 is stably derepressed (6, 10, 24) . Thus, this strain consistently possesses high levels of beta-lactamase in its periplasmic space and in this respect is phenotypically similar to strains with inducible beta-lactamases after cefoxitin treatment. The beta-lactam antibiotics to which strain P99 was resistant were the same drugs for which antagonism could be demonstrated with strains possessing inducible betalactamases. That the enzyme was responsible for this resistance in strain P99 was demonstrated by the susceptibility of its enzymeless mutant, P99-, to the drugs. Like the inducible enzymes in other strains, the P99 beta-lactamase did not inactivate all drugs to which it conferred resistance. Thus, beta-lactam resistance in P99 paralleled the antagonism observed with cefoxitin, and both appeared to be due either to enzymatic or barrier mechanisms.
The inability of cefoxitin to antagonize mecillinam and N-formimidoyl thienamycin and the susceptibility of E. cloacae P99 to these two drugs suggest that the enzyme-derived barrier is not equally effective for all drugs. Since mecillinam is not a good substrate for type I enzymes which have little affinity for the drug (18), neither antagonism by cefoxitin nor resistance in strain P99 was expected. However, N-formimidoyl thienamycin, like moxalactam and carbenicillin, is not a substrate for type I enzymes but is a potent suicide inhibitor of the enzymes (19, 20) . Thus, one might have expected antagonism and resistance to this drug, as occurred with moxalactam. Since none was observed, this suggests that the barrier is not equally effective for all drugs that can be bound by the enzymes. This difference in barrier efficiency may be related to differences in target proteins (penicillin-finding proteins, PBPs) in the cell. N-formimidoyl thienamycin, like mecillinam, binds primarily to PBP 2 (3, 26) , whereas carbenicillin, moxalactam, and other drugs antagonized by cefoxitin bind to PBPs 1A, 1B, 3, and many nonlethal PBPs (3, 13, 23, 26, 29) . Thus differences in barrier efficiency may result either from differences in (i) the number of target proteins that.must be bound by a drug for its antibacterial effect or (ii) the location of the beta-lactamase barrier relative to the lethal PBPs. In the first situation, under conditions of limited access to target proteins, drugs like carbenicillin and moxalactam that bind to many PBPs are greatly affected since the limited drug molecules passing the barrier bind both lethal and nonlethal PBPs. In contrast, drugs like N-formimidoyl thienamycin that bind only to a limited number of PBPs are less affected since each molecule passing the barrier is likely to bind a lethal PBP. In the second situation, the beta-lactamase barrier may be located in greater proximity to PBPs 1A, 1B, or 3. Thus, drugs with these PBPs as primary lethal targets would be more greatly affected than those binding primarily to PBP 2. Clearly, more extensive studies are required to delineate which of these two possibilities is responsible for the differences in the barrier efficiency observed in this study. However, there is a good association between low barrier efficiency and PBP 2 as a primary lethal target.
Although competition for binding proteins has been proposed as a mechanism responsible for cefoxitin's antagonism of some beta-lactams, this mechanism was not addressed in our study. However, the close correlation between the antagonism profile observed with strains with cefoxitin-inducible beta-lactamases and the resistance profile observed with a strain stably derepressed for enzyme production (in the absence of cefoxitin) makes this mechanism unlikely to be of great importance in the antagonisms reported here.
The clinical significance of these antagonisms is unknown. However, recently Kuck et al. have shown that cefoxitin antagonizes the in vivo efficacy of piperacillin or mezlocillin in an animal infection model (14) . Since cefoxitin does appear to be antagonistic to a variety of betalactam antibiotics in vitro, we designed an animal infection model to further assess cefoxitin's antagonistic potential in vivo. That study is the subject of the succeeding paper.
